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Abstract
Background: Little research has examined whether alcohol reduction interventions improve antiretroviral therapy
(ART) adherence and HIV treatment outcomes. This study assesses the efficacy of an intervention for reducing
alcohol use among HIV patients on ART who are hazardous/harmful drinkers. Specific aims include adapting a
blended Motivational Interviewing (MI) and Problem Solving Therapy (PST) intervention for use with HIV patients;
evaluating the efficacy of the intervention for reducing alcohol consumption; and assessing counsellors’ and
participants’ perceptions of the intervention.
Methods/Design: A randomised controlled trial will evaluate the intervention among ART patients in public
hospital-based HIV clinics in Tshwane, South Africa. We will recruit patients who are HIV-positive, on ART for at least
3 months, and classified as harmful/hazardous drinkers using the AUDIT-3. Eligible patients will be randomly assigned
to one of three conditions. Patients in the experimental group will receive the MI-PST intervention to reduce
harmful/hazardous alcohol use. Patients in the equal-attention wellness intervention group will receive an
intervention focused on addressing health risk behaviours. Patients in the control condition will receive treatment
as usual. Participants will complete an interviewer-administered questionnaire at baseline and 3, 6 and 12 months
post-randomisation to assess alcohol consumption, ART adherence, physical and mental health. We will also collect
biological specimens to test for recent alcohol consumption, CD4 counts and HIV RNA viral loads. The primary
outcome will be reduction in the volume of alcohol consumed. Secondary outcomes include reduction in harmful/
hazardous use of alcohol, reduction in biological markers of drinking, increase in adherence rates, reductions in viral
loads, and increases in CD4 T-cell counts. A process evaluation will ascertain counsellors’ and participants’ perceptions
of the acceptability and effectiveness of the interventions.
Discussion: We have obtained ethical approval and approval from the study sites and regional and provincial health
departments. The study has implications for clinicians, researchers and policy makers as it will provide efficacy data
on how to reduce harmful/hazardous alcohol consumption among HIV patients and will shed light on whether
reducing alcohol consumption impacts on HIV treatment adherence and other outcomes.
Trial registration: Pan African Clinical Trials Register Number: PACTR201405000815100.
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Background
The consumption of alcohol has been closely investi-
gated within the context of HIV [1]. Data suggests that
hazardous alcohol use directly contributes to the acqui-
sition and transmission of HIV as well as to antiretro-
viral therapy (ART) non-adherence, the worsening of
HIV disease, progression to AIDS, and mortality [2-4].
Not only does South Africa have high numbers of per-
sons who are HIV positive and on ART, but it also has
one of the highest levels of per capita alcohol con-
sumption per drinker globally and one of the highest
levels of heavy episodic drinking globally among men
and women [5].
ART is essential for improving and maintaining phys-
ical health, reducing HIV viral load, and reducing mor-
bidity and mortality among people living with HIV and
AIDS (PLWHA) [6]. Sub-optimal adherence to ART reg-
imens can result in the development of resistance to
ART, and ultimately poorer treatment outcomes, and
mortality [7-10]. Alcohol consumption is a concern in
relation to ART as alcohol may impact the cognitive pro-
cesses necessary to maintain adequate adherence [11].
Furthermore, beliefs that ART medications should not
be taken while consuming alcohol may cause drinkers to
fail to adhere to treatment [12-15]. Hendershot et al.’s
meta-analysis found that drinkers were 50%-60% as
likely to be adherent as non-drinkers [16]. This effect
was amplified for problem drinkers, who were only 47%
as likely to be adherent as non-problem drinkers or ab-
stainers. In addition, missed ART doses occur primarily
on drinking days [17]. In keeping with these findings,
the consumption of alcohol has been shown to be sig-
nificantly associated with time to ART treatment failure
as well as subsequent survival [18].
At a molecular level, in vitro experiments have dem-
onstrated that exposure to even a moderate dose of alco-
hol can increase HIV replication in peripheral blood
mononuclear cells [19]. Evidence suggests that alcohol
use may lead to an increase in HIV viral replication in
those infected with HIV [19-23]. Alcohol consumption
may also impact CD4 cells, with research demonstrating
lower CD4 counts among heavy alcohol users [24-26].
Despite the demonstrated links between alcohol con-
sumption and HIV, few randomised controlled trials
(RCTs) have evaluated the efficacy of alcohol-focused in-
terventions in the context of HIV treatment. Further-
more, when such interventions have been implemented,
the results have been equivocal [27-30]. There is consid-
erable evidence from systematic reviews of RCTs that
brief interventions (BI) are effective for reducing the
volume of alcohol consumed and hazardous/harmful
alcohol use among a range of patient populations, in-
cluding those receiving primary health care [31-33].
The brief interventions (BI) we have chosen are based on
motivational interviewing (MI) techniques and problem-
solving therapy (PST), a variant of cognitive-behavioural
therapy (CBT). Both of these modalities have proven effi-
cacy for reducing alcohol consumption and problem
drinking among a range of patient populations [34-38].
In the proposed study, we will bolster the effect of MI on
hazardous and harmful drinking and improve the dur-
ability of MI’s effects by blending MI techniques with
core elements of PST. Similar to MI, there is a large
body of evidence in support of the efficacy of CBT
for reducing problem drinking [38-41]. While the ele-
ments of this blended intervention are based on well-
established treatment modalities of proven efficacy, they
have not been implemented among PLWHA in South
Africa. However, findings from our earlier work suggest
that this blended intervention is likely to be acceptable to
this population [42].
The overall goal of this project is to improve know-
ledge on the efficacy of an alcohol reduction interven-
tion on alcohol consumption among PLWHA on ART,
ART adherence and HIV treatment outcomes. The study
has the following specific aims:
(i) To adapt a blended MI and PST intervention to
address harmful/hazardous alcohol use in HIV
positive populations in Tshwane, South Africa.
(ii) To assess the efficacy of the blended MI-PST
alcohol-focused intervention for reducing the
average volume of alcohol consumed, improving ART
adherence, maintaining ART adherence, improving
HIV treatment continuation, and reducing disease
progression relative to an equal-attention wellness
intervention and treatment as usual (TAU) control
group. We hypothesise that those patients who
receive the MI-PST alcohol-focused intervention
will be more likely than those in the wellness
intervention or TAU control groups to reduce their
volume of alcohol consumption (our primary
outcome) and that the participants in the
alcohol-reduction intervention who reduce their
alcohol consumption will have significantly greater
improvements in their degree of ART adherence and
in their HIV disease-related outcomes (including
their treatment continuation and the progression of
their disease) relative to participants in the wellness
intervention or control group.
(iii) To qualitatively assess counsellors’ and participants’
subjective responses to the blended MI-PST
intervention.
Methods/Design
The proposed project will comprise three phases corre-
sponding to the three specific aims. In Phase 1 (Aim 1),
we will adapt an existing blended MI-PST intervention
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for use among patients receiving treatment for HIV.
Phase 2 (Aim 2) will entail an RCT to assess the efficacy
of this blended intervention in reducing alcohol con-
sumption and in turn, improving levels of adherence to
ART and HIV disease outcomes among ART patients
in clinical care. Phase 3 (Aim 3) will involve a process
evaluation to assess the counsellors’ and participants’
perceptions of the acceptability and impact of the alco-
hol intervention.
Phase one: adapting MI-PST to reduce alcohol use among
PLWHA initiating ART
We will adapt and refine our MI-PST intervention mate-
rials for use among patients receiving HIV disease care
through conducting four focus group discussions (FGDs)
with up to eight patients per group. They will discuss
their perceptions about (1) how alcohol use relates to
ART adherence; (2) potential barriers and facilitators to
patient uptake of the proposed interventions; and (3) the
acceptability, appropriateness and relevance of the pro-
posed interventions. Each group discussion will be
audio-taped and transcribed. Participants will receive
refreshments during the FGDs, an incentive (a supermarket
voucher worth ZAR50, approximately US$4.76), and
ZAR50 for public transport to the clinics.
Once the intervention has been initially adapted, we
will train health counsellors to pilot the blended MI-PST
intervention for alcohol use and the MI-PST interven-
tion for the wellness intervention. This pilot will assess
the feasibility and acceptability of conducting these
interventions among PLWHA in clinical care settings
and test the intervention materials and procedures prior
to scaling up for the RCT. Up to 20 patients who meet
the eligibility criteria will be requested to provide in-
formed consent prior to assessment and participation in
the intervention. During the assessment, we will pre-test
the study’s battery of questions to get a sense of how
long it would take to complete the assessment as well
as whether there is a need to revise any parts of the
questionnaire.
In addition, we will pre-test the procedures for collec-
tion of biological specimens from the participants in
order to assess their HIV viral load and CD4 T-cell
counts, and Phosphatidylethanol (PEth), a biomarker
indicative of recent alcohol use. Participants will then re-
ceive either the 4 session blended MI-PST alcohol reduc-
tion or the equal attention MI-PST wellness intervention
over two days (Sessions 1 and 2 in Day 1, and Sessions 3
and 4 in Day 2).
Following the final intervention session, they will be
re-interviewed to assess their perceptions of the factors
that helped and hindered behaviour change. These inter-
views will be audio-taped and transcribed and used to
further refine the intervention materials prior to their
use in the RCT. Participants will receive an incentive
after completing each intervention session and for com-
pleting the follow-up interview. Equal effort will be put
into developing and adapting the alcohol and wellness
interventions.
Phase two: randomised controlled trial
Design
The proposed parallel, individual RCT will use a re-
peated measures design (see Figure 1, Consort diagram).
The study will be a three-arm comparison, with one pre-
intervention observation and three repeated measures
post-intervention observations per participant. Random-
isation to interventions will be done within sites.
Study population and sample size considerations
All participants will be recruited from ART clinics in
hospitals in the Tshwane Health District. The inclusion
criteria for the clinics include having funds for the dur-
ation of the project so that ART supplies do not run out,
being located within the Tshwane Health District, and
having a large active caseload of PLWHA receiving ART
(e.g. at least 100 per week) to facilitate patient recruit-
ment. Individuals will be eligible to participate in this
research if they (1) are HIV-positive; (2) have taken ART
for at least three months; (3) are not currently receiving
treatment for TB (or latent TB infection); (4) are 18 years
or older; (5) are classified as “harmful/hazardous drinkers”
(have six (or four, if female) or more drinks on one occa-
sion at least weekly, and score no more than 22 on the
AUDIT); (6) are resident in the Tshwane Metropolitan
Municipality or the general area served by the clinic/site;
(7) have no substantial cognitive impairment; (8) are not
currently enrolled in another trial; and (9) do not have ex-
tremely poor general health/functional status (Karnofsky
clinical score > 50).
Sample size estimates are based on the numbers of
patients needed to detect differences between interven-
tion and control groups in the mean number of drinks
per day (past 30/60 days) at 3, 6, and 12 months post
randomisation, our main outcome measure. A study
among HIV patients found that the mean number of
drinks per drinking days was 3.58 (Standard Deviation
(SD): 1.81) under an enhanced MI vs. 4.75 (SD: 3.22)
under the control arm [43]. For two-sided testing at a
significance level of 5% and power of 90%, with one
pre- and three post- intervention measures with a within
subject correlation of 0.7 between measurements, the re-
quired sample size using analysis of covariance methods
is 260. Of the 260 participants, 130 will be allocated to
the alcohol intervention and 65 to each of the wellness
and TAU arms. This imbalance of sample sizes for the
treatment combinations can cause loss of power of stat-
istical tests of differences between the group outcomes
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(e.g. means). It may also produce sensitive results in
small samples when the assumptions of equal variance
between groups are violated. Nonetheless, our choice of
the imbalanced design was based on valid scientific and
practical reasons, as the intervention combination we
plan to assess is of great interest. Thus, the higher sample
size in the main intervention arm (alcohol intervention)
was chosen as it is statistically more efficient to have
more subjects in this group as we will be comparing
its effect to each of the other two interventions. This
sample size also allows adequate power (>90%) to de-
tect a modest effect size (0.25) for the within-subjects
component, and for a potential interaction between-
and within-subjects factors. However, the actual num-
ber of participants needs to be inflated to take into
account attrition over time. We estimate an overall at-
trition rate of 20% and therefore need to recruit 325
participants to take into account this attrition. Assuming
Figure 1 Consort diagram of the study design.
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four sites, this would create a site-specific sample size of 82
(66 after attrition).
We have no site-specific hypotheses, but if we want to
include a safety margin for testing site specific effects of
0.30, we should allow for a site specific sample of 150
which would already include the attrition (120 per site
before attrition). Of these, 75 would receive the alcohol
intervention, and 38 each the wellness intervention and
TAU. We will recruit participants from each site without
an attempt to have equal numbers of men and women;
we anticipate a ratio of about 2:1 females to males.
Based on our prior data [44], we would estimate that
about 40% of ART recipients will be alcohol drinkers. Of
the alcohol drinkers, we estimate that about 15% would
meet the criterion related to alcohol (have six (or four, if
female) or more drinks on one occasion at least weekly,
and score no more than 22 on the AUDIT). That re-
search also suggests a participant eligibility rate of no
more than 20%, so we would need to screen at least 750
patients at each site to reach our target sample of 150.
Therefore we need to recruit participants from large fa-
cilities, suggesting that only hospital-based clinics would
qualify as possible study sites. Thus, we plan to recruit
participants from all four of the district hospitals in the
Tshwane Health District, which cover a wide catchment
area. The hospitals are: (1) Tshwane District Hospital,
(2) Pretoria West Hospital, (3) Odi District Hospital, and
(4) Jubilee Hospital. With four sites, our final sample
size of 600 will include 300, 150 and 150 participants in
the alcohol, wellness and TAU arms respectively. In the
proposed district hospitals, there are HIV clinics in the
form of separate outpatient departments (OPD). These
HIV clinics carry very high volumes of patients, spanning
the whole continuum of care.
Recruitment procedures
Within each study clinic, the research staff will identify
HIV-positive participants who have been on ART and
provide them with a brief overview of the study. Inter-
ested individuals will then be referred to a fieldworker,
who will request informed consent for the completion of
a brief screener for assessing whether or not they meet
the eligibility criteria listed above. With one of the pro-
posed inclusion criteria being classified as a “harmful/
hazardous drinker” (have six (or four, if female) or more
drinks on one occasion at least weekly, and score no
more than 22 on the AUDIT), those with AUDIT scores
in the range of possibly dependent (>22) will not be eli-
gible for the study, hence they will not get to the ran-
domisation stage. Once the participant has consented to
take part in the study he/she will be assigned a random
ID number which will determine the condition into
which he/she will be placed: the alcohol-reduction inter-
vention condition, the wellness intervention condition,
or the TAU condition. Consenting individuals will then
be asked to provide a sample of just under 25 ml of ven-
ous blood, to assess biomarkers that are indicative of re-
cent levels of alcohol consumption and assess their HIV
viral load and CD4 T-cell counts. The blood samples will
be drawn by a registered nurse or phlebotomist in a pri-
vate space and transported to a local laboratory for testing.
The participants will then be interviewed by a fieldworker
on their demographic characteristics, alcohol-related is-
sues, ART adherence, and health-related issues. The inter-
views will be conducted by a trained interviewer who will
be independent of the interventionists and clinic staff. Par-
ticipants assigned to the alcohol reduction and wellness
conditions will then be asked to return within one week
(or two weeks, if not available during the following week)
to receive their first and second intervention sessions, and
return after another week, to receive their third and fourth
intervention sessions. All participants, irrespective of con-
dition assignment will be asked to return at three, six and
twelve months’ post-randomisation to complete follow-up
assessments (interviews and further biological testing).
Participants’ transport costs will be covered for each con-
tact with project staff.
Randomisation and blinding
Randomisation to one of the three conditions will occur
at each of the four sites, i.e. the randomisation will be
stratified by site. The randomisation code will be gener-
ated by computer generated tables. Treatment allocation
will be done by site supervisors using pre-prepared con-
secutively numbered sealed, opaque envelopes, which
will contain the group assignment. Fieldworkers will con-
duct the post-intervention outcome assessments masked
to treatment allocation to ensure that the assessments re-
main unbiased and independent from the intervention
sessions. Each counsellor will take part in only one inter-
vention arm, and the wellness and alcohol reduction
interventions will be run on different days of the week
(based on alternating biweekly schedule) to minimise
contact between participants who are randomly allocated
to different arms, and to minimise contamination across
the study arms. Given the study’s behavioural nature, the
interventionists will not be blinded to which intervention
the participants receive.
Intervention conditions
Condition 1: Blended MI and PST for alcohol The
overall goals of this blended intervention are to motivate
participants to reduce their hazardous or harmful drink-
ing and equip them with problem-solving skills that will
improve their ability to cope with alcohol use triggers.
This experimental condition will comprise four modules
conducted over two sessions, with these sessions spread
one week apart (Table 1). These four sessions allow us
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to cover all of the core principles of PST and allow time
for practicing of skills. In formative research to deter-
mine the appropriateness and acceptability of our MI-
PST intervention for patients attending primary health
care services, one hour was the most preferred session
length, and the vast majority of patients were willing to
return to the clinic for two to three extra visits. Hence
we have tailored this intervention to meet patients’ pref-
erences [45]. Each session iteratively builds upon partici-
pants’ readiness to change and the problem-solving and
coping skills developed in the previous session, and has
a motivational, educational and practical component.
The sessions’ structure conforms to our previous re-
search observations that ART recipients most preferred
one-hour long sessions, and two-session interventions.
Condition 2: Blended MI-PST for wellness The well-
ness intervention will be an equal attention-control arm.
Like the alcohol reduction intervention, this intervention
will incorporate MI-PST techniques to promote reduc-
tion of health risk behaviours, healthy nutrition and a
healthy lifestyle. It will be delivered across four sessions,
with Sessions 1 and 2 occurring in Week 1 (separated
by a break) and Sessions 3 and 4 occurring in Week 2.
Participants will be taught about healthy eating, to main-
tain a healthy weight, and the value of exercise for
optimum health.
Condition 3: Treatment as usual (TAU) Participants
in this condition will receive the standard package of care
for PLWHA and on ART who also drink at hazardous/
harmful levels. Typically, if a health care provider suspects
adherence problems (by self-report or clinical indicators),
the patient is referred to adherence counsellors for add-
itional counselling. There are no firm guidelines on the
duration or content of this counselling. Counsellors are
left to determine how best to address adherence problems
with the patient. If adherence counsellors or primary
Table 1 Blended motivational interviewing (MI) and problem solving therapy (PST) intervention
Summary of blended MI and PST sessions and objectives
Session 1, Week 1 45 minutes • Conduct screening/assessment of alcohol use
• Provide feedback on results of screening/assessment
• Increase knowledge of how alcohol use impacts on course of HIV
• Use MI to build rapport and develop readiness to change
○ Assess readiness to change (using readiness ruler)
○ Assess pros and cons of change (Decision-balance exercise)
○ Use MI to try and shift participant and elicit a commitment to change
Session 2, Week 1 Patient check-in (using MI)
50 minutes • Build the Rationale for PST
• Explain the structure of PST
• Explain the link between problems and alcohol use, and the rationale for PST
• Establish positive problem orientation
• Describe the steps of PST
• Build the rationale for activity scheduling
• Describe the steps of Problem Solving
• First Problem Solving Session with counsellor (using the steps) and describe homework
Session 3, Week 2 50 minutes • Patient check-in (using MI)
• Review homework from previous week and challenges/difficulties
○ Elicit positive change talk and affirm commitment to change using MI techniques
○ Review PST steps and affirm attempts to change
• Explain what can be done about problems that are not important (coping with negative thoughts)
• Second Problem Solving Session with counsellor and an exercise
Session 4 Week 2 45 minutes • Review practice exercises from session 3
• Explain what can be done about problems that are important but cannot be solved 5 min (advancing the
process of acceptance)
• Third Problem Solving Session with counsellor and recap
• Elicit positive change talk and affirm commitment to change using MI techniques
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health care providers suspect alcohol problems, they usu-
ally refer patients to on-site clinical psychologists/clinical
social workers, if available, or off-site community mental
health (CMH) or alcohol services. We will monitor the
number of visits the TAU patients make for adherence
and alcohol support, and type(s) of support services re-
ceived (e.g. advice, referral) by means of self-report at the
3, 6, and 12 month follow-ups.
Follow-Up
Participants will be followed-up on three occasions: at
three, six and 12 months (Table 2). At each follow-up
visit, they will be interviewed using a structured ques-
tionnaire. They will have blood drawn for the following
tests: viral load (at baseline and 12-month follow-up);
CD4-T cell count (at each follow-up point); and alcohol
biomarker PEth (at each follow-up point). Compensation
will be provided to participants in all arms in the form
of shopping vouchers for completion of the follow-up
assessments.
Participant retention
In order to enhance participant retention we will: (1) in-
form interested individuals at recruitment that participa-
tion in the study will last for 12 months, and that if they
anticipate relocating to another area or clinic they will
not be eligible to participate. (2) Ask participants to
provide their own and two close relatives’ or friends’ con-
tact details, including telephone numbers and physical ad-
dresses to facilitate regular contact with them, reminder
calls, and other participant tracking efforts.
Measures
We will use a structured questionnaire at baseline and
each follow-up period. It will be available in English,
Afrikaans and seTswana. We will assess the following:
 Demographic Characteristics. We will assess
participants’ age, gender, race/ethnicity, income,
education, employment status, housing status,
relationship status, sources of income and food
insecurity.
 Alcohol Consumption. Multiple self-report measures
will be used to assess various dimensions of alcohol
consumption. The Alcohol Use Disorders Identification
Test (AUDIT) [46] will be employed as part of
the initial screening process, as well as all further
follow-up assessments to identify potential harmful
and hazardous drinking. We will change the reporting
period of the AUDIT from 12 months to 3 months
at baseline and at each of the follow-up periods.
We will only ask participants to respond to the
AUDIT questions for the past 12 months during
the screening. Additional items will assess current
drinking/abstention (past 90 days, past 12 months
and lifetime). The 3-month quantity item will serve
as the primary behavioural outcome measures for
alcohol consumption, together with a combined
quantity-frequency measure.
 Social Problem Solving Styles. We will employ the
25-item Social Problem-Solving Inventory Revised-
Short Form (SPSI-R: SF) [47], which measures
problem solving styles. Previous South African
Table 2 List of study instruments, data elements and source of information
Data collection instruments Time period Data collected Source
Screening questionnaire Day of enrolment Eligibility assessment Self-report
Participant assessment Baseline 3, 6, and 12 month follow up Demographic information, alcohol consumption,
social problem solving styles, motivation/readiness
to change, antiretroviral therapy (ART) history,
adherence to ART, psychosocial factors associated
with ART adherence (disclosure, HIV/AIDS stigma,
social support, adherence self-efficacy), alcohol
and ART beliefs, HIV-related factors (e.g. degree of
ill-health between HIV diagnosis and ART initiation),
clinical/structural factors (e.g. length of time to
doctor), physical functioning (e.g. limitations due
to physical health, bodily pain, vitality), general
physical well-being, mental well-being, drug and
tobacco use
Self-report
Laboratory report form Baseline, 3, 6, 12 month follow up HIV-related outcomes: viral load (baseline and
12-month follow up assessments only) and
CD4 counts
Laboratory report
Alcohol biomarkers: Posphatidylethanol (PEth)
Process evaluation interview
schedule
12-months follow-up A randomly selected 10% subsample will respond
to a qualitative interview regarding impressions of
the degree to which the intervention helped or
hindered behaviour change
Self-report
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studies have obtained Cronbach’s alphas of 0.72-
0.83 for this scale [48].
 Motivation/Readiness to Change. The participants
will be asked to respond to the 12-item Readiness to
Change Questionnaire to determine their readiness
to change their drinking behaviour [49].
 Adherence to ART. Four adherence measures will
form the basis of the self-reported ART adherence
outcomes: (1) The AIDS Clinical Trials Group
(ACTG) adherence questionnaire; which assesses
patients’ current ART medications, dosing schedule,
and medication doses missed over the past four days
[50]; (2) The Visual Analog Scale (VAS), which
assesses general levels of adherence over a 30-day
timeframe [51]. For the ACTG and VAS, adherence
levels will be examined in terms of both continuous
and dichotomous measures (e.g. cut-offs of 90%,
95%, and 100% adherence rates); (3) The CASE
Adherence Index [52]; and (4) The Self-Rating Scale
Item (SRSI) [53,54].
 Health Functioning. The SF-8 is an eight item
measure of health and well-being, assessing physical
functioning, limitations due to physical health, bodily
pain, general health, vitality, social functioning,
limitations due to emotional health, and mental
health issues [55].
 Mental Well-Being. The Kessler Psychological Distress
Scale-10 [56] will be used to assess psychological
distress.
 Drug and Tobacco use. The Drug Use Disorders
Identification Test (DUDIT) [57] is an 11-item
self-report measure that will be used to assess
concurrent substance use. Participants will also
be assessed for tobacco use (including lifetime,
current and regular cigarette smoking) and tobacco
dependence using the Fagerstrom Test for Nicotine
Dependence (FTND) [58].
 Alcohol Biomarkers. In addition to the use of self-
report measures of alcohol use, tests of the alcohol
biomarker, Phosphatidylethanol (PEth) [59,60] will
be conducted among all participants at each time
point.
 Clinical/Structural Factors. The following structural
factors typically associated with ART adherence will
be assessed: Time to doctor; difficulty getting to the
clinic. These are reasons for difficulty getting to the
clinic. Based on previous research with HIV clinic
patients in South Africa [61].
 HIV-Related Factors. The following information will
be obtained: perceived year and month of diagnosis;
perceived current HIV viral load and CD4 cell
count, advent of opportunistic infections, the degree
of ill health between diagnosis and starting on ART,
and the duration from diagnosis to ART enrolment.
 ART History. We will assess the duration of being
on ART and duration on the current regimen.
 Psychosocial Factors. Psychosocial factors typically
associated with ART adherence will be assessed. For
example, HIV stigma will be measured with the
Internalised AIDS-Related Stigma Scale [12], HIV
disclosure will be assessed via a measure used in our
prior studies [42,44], social support will be assessed by
the MOS Social Support Survey [62], and adherence
self-efficacy will be assessed by the HIV Treatment
Adherence Self-Efficacy Scale (HIV-ASES) [63].
 General Physical Well-being. The Karnofsky
Performance Scale will be used to evaluate the
general health/functional status of prospective
participants. Scores range from 0 to 100; the lower
the score, the more compromised general well-being
[64,65]. Individuals with a Karnofsky clinical score
below 50 will not be eligible for participation.
 Alcohol and ART. We will ask about (1) the source(s)
of participants’ knowledge about alcohol use and
ART; (2) beliefs about alcohol and ART; (3) beliefs
about the acceptability of drinking while on ART; and
(4) patterns of drinking while on ART.
 Screening for Cognitive Impairment. We will use the
International HIV Dementia Scale (IHDS) [66] to
screen for substantial cognitive impairment. The
cut-off score on this instrument is 10.
Phase 3: process evaluation
Following the final follow-up assessment, we will ran-
domly select 10% of participants (from the wellness and
MI-PST conditions) for qualitative in-depth interviews.
These interviews will assess participants’ impressions of
the degree to which they felt the intervention helped or
hindered behaviour change. They will be conducted by
project staff not involved in the assessments or interven-
tions in order to minimise response bias. The qualitative
interviews will be conducted in the participants’ lan-
guage of choice. All interviews will be audio-taped and
transcribed verbatim. Findings from these qualitative in-
terviews will be used to interpret and better understand
the quantitative findings from the RCT. Participants will
receive an incentive for their time and participation in
these interviews and a voucher to cover transport costs.
Study timeline
The first nine months of the study will involve inter-
vention and measurement development, piloting of
intervention components and training field staff and
counsellors. Study recruitment will be conducted at the
end of Year 1 and during the first 3 months of Year 2. If
necessary, timelines may be adjusted based on informa-
tion gained during the pilot phase. Intervention sessions
will commence in the last quarter of Year 1 and continue
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during the first half of Year 2. Three and six month
follow-up assessments will be conducted in Year 2.
Twelve-month follow-up assessments will be conducted
in Year 3. Quarters 3–4 of Year 3 will involve data syn-
thesis, analysis, write-up and dissemination.
Statistical treatment and analysis of data
Analyses for phase 1
All audiotapes will be transcribed into MS Word. MS
Word documents will be imported into Nvivo 10 [67].
Data analysis will be conducted using the framework
approach (familiarization, identifying a thematic frame-
work, indexing, charting, mapping and interpretation).
Initially, transcripts will be read for emergent themes,
which will then be coded. Coding and analysis will con-
tinue iteratively as new themes and issues emerge; all
relevant information will be retrieved and examined for
further coding designations. To establish inter-coder re-
liability, each transcript will be coded by at least two
individuals. Coding discrepancies will be discussed and
resolved and transcripts will be subjected to checks until
the Cohen’s Kappa score reaches 70% agreement. We will
use these findings to assist with revisions to our proposed
intervention materials and implementation protocols.
Analyses for phase 2
Given the repeated measures design, the main statistical
analysis will involve repeated analysis of variance and
analysis of covariance, using pre-treatment means and
post-treatment means; or two-sample t-tests or chi-
squared tests at the patient level data. The hypothesis
that alcohol reduction will increase adherence will be
tested via a repeated-measures Analysis of Variance
(ANOVA). This will be an intent-to-treat (ITT) analysis.
For our ITT analysis we will analyse our data based on
the participants’ original allocation to the groups regard-
less of any subsequent group changes or participants’ de-
gree of adherence to study protocols or their withdrawal
from the study. We will assume data will be missing
completely at random (MCAR) in order to enable im-
putation of missing data using standard techniques. We
have postulated a main effect for the experimental con-
dition without an interaction effect. In addition, we in-
tend to use the CD4 T-cell counts and viral loads as
objective biological endpoints, with the same statistical
procedure being employed. Additional analyses will de-
termine whether the pathway via reduction of alcohol
consumption was indeed crucial to the differences in ad-
herence. This can be measured by a cross-lagged panel
design, where the alcohol in the time interval before the
respective measurement of adherence will be assumed to
have a significant effect. Structural equation modelling
and path analysis will be used to test this assumption.
Models will also be run with ART continuation as the
endpoint. More advanced techniques, including general-
ised estimating equation and multilevel modelling, will
also be employed. The association between the bio-
marker of alcohol consumption and self-reports of alco-
hol will be analysed using correlation and regression
techniques with adjustments for possible confounders.
The predictive ability of the biomarker will be assessed
using sensitivity and specificity techniques to determine
its ability to detect excessive self-reported consumption
of alcohol.
Analyses for phase 3
Data analysis will be conducted using the same frame-
work approach as described above for Phase 1. We will
use the Phase 3 findings to assist with interpreting the
findings of the RCT phase.
Ethics
Paper-based data will be stored in locked filing cabinets
at the MRC offices in Pretoria for five years. Study data
and consent forms will always be stored apart from each
other in separate locked filing cabinets. Electronic data
files will be encrypted, password protected and saved
onto secure computers. Samples will be identified by
their study identification number and will not include
participants’ names.
In order to secure quality control and quality assur-
ance of the study, research staff and counsellors will re-
ceive training in research ethics for human subjects.
Second, a data manager will be employed to ensure ac-
curate data collection; the maintenance of participant
confidentiality; and the secure transfer and storage of
electronic data. Third, weekly feedback meetings will
be held among study personnel, the data manager, and
the project manager and will address possible problems.
Separate weekly meetings will be held with the project
manager and PIs. Fourth, a Data and Safety Monitoring
Board (DSMB) will review study-related concerns (e.g.
adverse events) that may arise and will meet six-monthly.
Finally, independent study monitors will review study pro-
tocols and procedures (e.g. data collection and storage), at
two points during the data collection phase.
Safeguards will be implemented throughout the pro-
ject to protect participant confidentiality, as described
in the Human Subjects Protection Plan section, and to
minimize the risk of potential physical and psychological
harms. All procedures will first be pilot tested for ac-
ceptability with a small sample of individuals from the
target population, and any study-related activities identified
as harmful or as a cause of discomfort will be amended.
Ethical approval for this study has been obtained
from the Medical Research Council’s Ethics Committee.
Approval to conduct the study has also been obtained from
the Regional and Provincial Departments of Health, and
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the site managers of each clinic. Participants will be in-
formed that their decision to participate in the study is vol-
untary and will not affect their current or future care at the
clinic. They will also be informed that even after deciding
to participate in the study, they can still decline to answer
questions or to take part in specific activities, and they may
terminate their participation at any time without any pen-
alty. Informed consent will be obtained by research staff
who are not clinic employees or connected to participants’
medical care. Through the informed consent process, pro-
spective participants will be informed of all foreseeable
risks involved in the study. Individuals with low or no liter-
acy will have the consent form read to them by a person of
their choosing, and verbal consent will be obtained, wit-
nessed by an independent person. The consent forms will
be translated and back-translated and adapted for cul-
tural appropriateness and readability into SeTswana
and seSotho, the main local languages of the region.
To ensure confidentiality, study data and biological
samples will be identifiable only by randomly generated
participant identification numbers and will not contain
participants’ names or any other personal identifying in-
formation or protected health information. All electronic
data sources will be encrypted and password protected.
Research personnel who have contact with participants
will be asked to sign a confidentiality agreement, and re-
ceive on-going training and supervision on ethical conduct
and confidentiality protection. To minimise the possibility
of a breach of confidentiality by participants during the
focus group discussions, the participants will be asked to
not disclose the identity or the content of the commentary
of any of their fellow focus group discussion members to
anyone outside of the focus group.
Overall, only minimal risks are anticipated. Some partici-
pants may feel uncomfortable when answering the assess-
ment questions which address sensitive topics (e.g. alcohol
use; non-adherence); and/or when discussing their alcohol
consumption with the intervention counsellors; and/or
when providing blood samples. There are potential benefits
to study participants. Any individual identified as alcohol
dependent will be referred for alcohol treatment services.
Individuals assigned to the alcohol reduction condition are
expected to reduce their alcohol consumption, and in turn
improvements in their level of ART adherence, and their
HIV disease course. Moreover, at the end of the inter-
vention period clinic staff (and/or other suitable health
workers) will benefit as they will be trained on delivering
the intervention aimed at reducing harmful/hazardous
alcohol consumption. Finally, there is substantial public
health knowledge to be gained from this research.
Discussion
We hypothesize that compared to individuals who re-
ceive the wellness-focused BI, those who receive the
alcohol-focused BI will demonstrate greater reductions in
alcohol consumption, and as a result, they will demon-
strate higher levels of ART adherence and higher CD4
counts, and will be less likely to have detectable HIV viral
loads. This study will indicate whether alcohol-focused
interventions are feasible to implement with clinical HIV
populations, and also whether they can be used to
successfully improve adherence to ART treatment and
health-related outcomes among people being treated for
their HIV infection.
The proposed study has the potential to advance sci-
entific knowledge in several ways. First, it will be among
the first to use a blended MI and PST intervention to
target reductions in alcohol use among PLWHA in clin-
ical settings in South Africa. While evidence of the link
between alcohol use and poor adherence to ART has led
for calls for behavioural interventions to reduce risky
drinking among PLWHA, there have been few interven-
tions implemented in clinical settings to address this risk
for poor HIV disease outcomes. This study will not only
help us answer questions about whether reducing haz-
ardous and harmful alcohol use will lead to improved
adherence and HIV disease outcomes but will also pro-
vide knowledge about what kinds of behavioural inter-
ventions are effective for reducing hazardous/harmful
alcohol use among PLWHA in clinical care.
Second, this study hopes to further explain the rela-
tionship between alcohol use, ART adherence and HIV
disease outcomes. If the proposed intervention is effect-
ive, we hope to find that reduced alcohol use facilitates
better adherence to ART and consequently improved
disease outcomes. This would be a significant contribu-
tion to health knowledge and could lead to the develop-
ment of clinical guidelines for the management of
alcohol use among people living with HIV/AIDS. Third,
through the employment of alcohol and HIV disease-
related biomarkers to assess intervention efficacy, this
study will be at the forefront of research conducted in
the area of alcohol reduction and ART adherence pro-
motion, and will provide considerable objective data re-
garding the links between alcohol consumption, ART
adherence, and health outcomes.
Finally, testing the proposed intervention in clinical
settings is expected to yield valuable information about
how best to introduce and implement the proposed
intervention into clinical services. This information will
help lay a solid foundation for future studies that exam-
ine how best to integrate behavioural interventions for
alcohol use and other psychosocial risks for poor ART
adherence and HIV disease outcomes into HIV treat-
ment services. Taken together, results from this work
could have far-reaching implications for the develop-
ment and implementation of clinic-based programmes
as well as broader policies designed to reduce alcohol
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consumption, which in turn, can help improve the health
and well-being of those living with HIV/AIDS.
Any individual identified as alcohol dependent during
the screening process or during the course of the study
will be provided with a referral for alcohol treatment.
For individuals taking part in the study who are assigned
to the active treatment condition (MI/PST), it is antici-
pated that the alcohol counselling that is provided will
not only help to reduce their alcohol consumption, but
it may also help them improve their level of adherence,
which in turn could help decrease the likelihood of
worsening the course of their HIV disease and the
acquisition of opportunistic infections. With improve-
ments in ART adherence stemming from the interven-
tion, participants should also experience reductions in
their HIV viral load. This, in turn, can have a significant
public health benefit, whereby this decreased infectivity
can result in a reduced likelihood of participants passing
on HIV to their partners through unprotected sexual
contact [68,69]. Finally, should the intervention be found
to be effective, we will offer training to existing staff at
the four clinics (and/or other suitable health workers) in
how to screen and identify individuals whose drinking
may be detrimental to their health and also in how to
deliver psychosocial interventions aimed at reducing
harmful and hazardous alcohol consumption.
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